Movement Alert｜Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan

Market Focus06-25

On June 24, Natera rose 9.14% in regular trading, trading at approximately $256.15/share, with turnover of $2.78 billion. The rally was driven by the announcement that Natera's molecular residual disease (MRD) test, Signatera, received regulatory clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for use in colorectal cancer patients.

The approval makes Signatera the first and only officially approved MRD testing tool in Japan, designated to guide post-surgical adjuvant treatment decisions for colorectal cancer patients. The clearance was based on data from the Galaxy clinical trial, which demonstrated that chemotherapy provided benefit to MRD-positive patients after surgery while showing no significant effect in MRD-negative patients. Natera stated that commercial availability in Japan is expected by year-end, subject to final reimbursement approval and pricing decisions.

This regulatory milestone expands Natera's international footprint for its oncology diagnostics portfolio and opens access to the Japanese market, one of the largest healthcare markets globally.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150914615?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 00:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150914615","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan","media":"Market Focus","content":"<p><p>On June 24, Natera rose 9.14% in regular trading, trading at approximately $256.15/share, with turnover of $2.78 billion. The rally was driven by the announcement that Natera's molecular residual disease (MRD) test, Signatera, received regulatory clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for use in colorectal cancer patients.</p><p>The approval makes Signatera the first and only officially approved MRD testing tool in Japan, designated to guide post-surgical adjuvant treatment decisions for colorectal cancer patients. The clearance was based on data from the Galaxy clinical trial, which demonstrated that chemotherapy provided benefit to MRD-positive patients after surgery while showing no significant effect in MRD-negative patients. Natera stated that commercial availability in Japan is expected by year-end, subject to final reimbursement approval and pricing decisions.</p><p>This regulatory milestone expands Natera's international footprint for its oncology diagnostics portfolio and opens access to the Japanese market, one of the largest healthcare markets globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Natera Rises 9.14% in Regular Trading, Signatera MRD Test Secures Regulatory Approval in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 00:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Natera rose 9.14% in regular trading, trading at approximately $256.15/share, with turnover of $2.78 billion. The rally was driven by the announcement that Natera's molecular residual disease (MRD) test, Signatera, received regulatory clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for use in colorectal cancer patients.</p><p>The approval makes Signatera the first and only officially approved MRD testing tool in Japan, designated to guide post-surgical adjuvant treatment decisions for colorectal cancer patients. The clearance was based on data from the Galaxy clinical trial, which demonstrated that chemotherapy provided benefit to MRD-positive patients after surgery while showing no significant effect in MRD-negative patients. Natera stated that commercial availability in Japan is expected by year-end, subject to final reimbursement approval and pricing decisions.</p><p>This regulatory milestone expands Natera's international footprint for its oncology diagnostics portfolio and opens access to the Japanese market, one of the largest healthcare markets globally.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTRA","symbol_name":"Natera, Inc.","start_time":0,"source_url":"","article_id":"1150914615","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150914615","pubTimestamp":1782317597,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Natera rose 9.14% in regular trading, trading at approximately $256.15/share, with turnover of $2.78 billion. The rally was driven by the announcement that Natera's molecular residual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTRA":"Natera, Inc."},"translate_title":"动向提示|Natera常规交易涨9.14%Signatera MRD测试获日本监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1},"content_text":"On June 24, Natera rose 9.14% in regular trading, trading at approximately $256.15/share, with turnover of $2.78 billion. The rally was driven by the announcement that Natera's molecular residual disease (MRD) test, Signatera, received regulatory clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for use in colorectal cancer patients.The approval makes Signatera the first and only officially approved MRD testing tool in Japan, designated to guide post-surgical adjuvant treatment decisions for colorectal cancer patients. The clearance was based on data from the Galaxy clinical trial, which demonstrated that chemotherapy provided benefit to MRD-positive patients after surgery while showing no significant effect in MRD-negative patients. Natera stated that commercial availability in Japan is expected by year-end, subject to final reimbursement approval and pricing decisions.This regulatory milestone expands Natera's international footprint for its oncology diagnostics portfolio and opens access to the Japanese market, one of the largest healthcare markets globally.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150914615","isCrawlerRequest":true}